Northern Trust
CRNX icon

Northern Trust’s Crinetics Pharmaceuticals CRNX Stock Holding History

Northern Trust’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.6M Buy
841,301
+71,478
+9% +$3.19M ﹤0.01% 1425
2025
Q4 		$35.8M Sell
769,823
-40,065
-5% -$1.78M ﹤0.01% 1317
2025
Q3 		$33.7M Buy
809,888
+25,675
+3% +$821K ﹤0.01% 1364
2025
Q2 		$22.6M Sell
784,213
-72,868
-9% -$2.25M ﹤0.01% 1574
2025
Q1 		$28.7M Sell
857,081
-22,733
-3% -$849K ﹤0.01% 1414
2024
Q4 		$45M Buy
879,814
+149,298
+20% +$8.35M 0.01% 1192
2024
Q3 		$37.3M Buy
730,516
+124,479
+21% +$6.42M 0.01% 1223
2024
Q2 		$27.1M Buy
606,037
+4,653
+0.8% +$215K ﹤0.01% 1365
2024
Q1 		$28.2M Sell
601,384
-1,038
-0.2% -$40.6K ﹤0.01% 1360
2023
Q4 		$21.4M Buy
602,422
+5,098
+0.9% +$156K ﹤0.01% 1567
2023
Q3 		$17.8M Buy
597,324
+106,594
+22% +$2.2M ﹤0.01% 1626
2023
Q2 		$8.84M Buy
490,730
+13,442
+3% +$268K ﹤0.01% 2152
2023
Q1 		$7.67M Sell
477,288
-3,512
-0.7% -$65K ﹤0.01% 2201
2022
Q4 		$8.8M Buy
480,800
+2,418
+0.5% +$42.6K ﹤0.01% 2094
2022
Q3 		$9.39M Sell
478,382
-5,899
-1% -$120K ﹤0.01% 2018
2022
Q2 		$9.03M Buy
484,281
+43,757
+10% +$873K ﹤0.01% 2103
2022
Q1 		$9.67M Sell
440,524
-10,004
-2% -$202K ﹤0.01% 2164
2021
Q4 		$12.8M Buy
450,528
+83,529
+23% +$2.06M ﹤0.01% 2067
2021
Q3 		$7.72M Buy
366,999
+885
+0.2% +$18.5K ﹤0.01% 2463
2021
Q2 		$6.9M Buy
366,114
+70,721
+24% +$1.24M ﹤0.01% 2627
2021
Q1 		$4.51M Sell
295,393
-22,143
-7% -$343K ﹤0.01% 2821
2020
Q4 		$4.48M Sell
317,536
-8,145
-3% -$113K ﹤0.01% 2743
2020
Q3 		$5.1M Buy
325,681
+115,751
+55% +$1.77M ﹤0.01% 2514
2020
Q2 		$3.68M Buy
209,930
+47,585
+29% +$811K ﹤0.01% 2702
2020
Q1 		$2.39M Buy
162,345
+13,903
+9% +$285K ﹤0.01% 2755
2019
Q4 		$3.73M Buy
148,442
+12,793
+9% +$244K ﹤0.01% 2765
2019
Q3 		$2.04M Buy
135,649
+27,905
+26% +$543K ﹤0.01% 3097
2019
Q2 		$2.69M Buy
107,744
+3,415
+3% +$84.6K ﹤0.01% 2897
2019
Q1 		$2.38M Buy
104,329
+27,602
+36% +$678K ﹤0.01% 2967
2018
Q4 		$2.3M Buy
76,727
+498
+0.7% +$14K ﹤0.01% 2969
2018
Q3 		$2.18M Buy
+76,229
New +$2.26M ﹤0.01% 3166

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Northern Trust's CRNX Position: Q1 2026 in Review

Northern Trust increased its Crinetics Pharmaceuticals (CRNX) stake by 9.3% in Q1 2026, buying an estimated $3.19M and bringing the position to 841,301 shares worth $30.6M. The position accounts for ﹤0.01% of the portfolio, ranked #1425.

Northern Trust first reported a position in CRNX in Q3 2018 and has held it in 31 quarters since. The position peaked at $45M in Q4 2024. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Northern Trust held 841,301 shares of Crinetics Pharmaceuticals worth $30.6M as of Q1 2026.
  • Northern Trust bought 71,478 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $3.19M.
  • Crinetics Pharmaceuticals made up ﹤0.01% of Northern Trust's portfolio in Q1 2026, its #1425 holding.
  • Northern Trust first reported a position in Crinetics Pharmaceuticals in Q3 2018 and has held it in 31 quarters since.
  • Northern Trust's Crinetics Pharmaceuticals position peaked at $45M in Q4 2024.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Northern Trust's 13F filing for Q1 2026, filed 14 May 2026.